FindTrial
Sign In

The effect of fludrocortisone on the processing of personally relevant information by healthy people.

The effect of fludrocortisone on emotional information processing in healthy volunteers - Fludrocortisone and emotional information processing

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-005205-71-NL
Enrollment
Unknown
Registered
2012-02-10
Start date
2012-04-24
Completion date
Unknown
Last updated
2012-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None.

Interventions

Trade Name: Florinef Product Name: fludrocortisone acetate Product Code: florinef Pharmaceutical Form: Capsule, hard INN or Proposed INN: FLUDROCORTISONE CAS Number: 127-31-1 Current Sponsor code: FC

Sponsors

Leiden University
Lead Sponsor
Leiden University Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Females - Age 18-35yrs - BMI between 18 and 30 - Fluent in Dutch - North-West European ancestry Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Major physical illness (infections, diabetes, thyroid disease, epilepsy, multiple sclerosis, pituitary disease or any other serious medical condition). - Hypertension or history of stroke. Increased blood clot formation. - Any current or past psychiatric disorder. - Use of medication likely to interfere with the study (e.g., benzodiazepines, St John’s Wort). - Pregnancy or breastfeeding. - Use of soft drugs (hash, marijuana) in the three months prior to the study. - Any hard drug use during life time (including XTC). - Alcohol use of more than 14 units per week or more than 4 units on any day during the week prior to the study. - Regular smoker during past year or use of any nicotine products during past month

Design outcomes

Primary

MeasureTime frame
Timepoint(s) of evaluation of this end point: 2 hrs after intervention ;Main Objective: To determine the initial emotional and cognitive effects of MR-stimulation by acute administration of the specific MR-agonist fludrocortisone;Secondary Objective: None. ;Primary end point(s): - Accuracy of recognition of facial expressions of emotions - Memory for positive vs negative information—

Secondary

MeasureTime frame
Secondary end point(s): None. ;Timepoint(s) of evaluation of this end point: not applicable—

Countries

Netherlands

Contacts

Public ContactInstitute of Psychology

Leiden Univ

vanderdoes@fsw.leidenuniv.nl3171527 8482

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026